Application of a Novel ‘Make and Test in Parallel’ Strategy to Investigate the Effect of Formulation on the Pharmacokinetics of GDC-0810 in Healthy Subjects.

Autor: Cheeti, Sravanthi, Hou, Hao Helen, Nelson, Eric, Walker, Helen, Chen, Buyun, Morley, Roland, Gates, Mary, Musib, Luna, Girish, Sandhya, Sahasranaman, Srikumar, Liu, Lichuan
Předmět:
Zdroj: Pharmaceutical Research; Dec2018, Vol. 35 Issue 12, p1-1, 1p, 2 Diagrams, 4 Charts, 1 Graph
Abstrakt: Purpose: GDC-0810, administered orally, was used in Phase I and II clinical studies to treat estrogen receptor positive breast cancers. It contains N-methyl-D-glucamine (NMG) salt of GDC-0810 with 10% sodium lauryl sulfate (SLS) as a surfactant and 15% sodium bicarbonate (NaHCO3) as an alkalizing agent to aid dissolution. To improve the processability of the formulation and reduce potential mucosal irritation in future Phase III clinical studies, the salt form and the amount of excipient required further optimization. To achieve this, we employed a novel “Make and Test in Parallel” strategy that facilitated selecting formulation in a rapid timeframe.Methods: RapidFACT®, a streamlined, data-driven drug product optimization platform was used to bridge Phase I/II and Phase III formulations of GDC-0810. Five prototype formulations, varying in either the form of active pharmaceutical ingredient and/or the levels of the excipients SLS and NaHCO3 were assessed. Uniquely, the specific compositions of formulations manufactured and dosed were selected in real-time from emerging clinical data.Results: The study successfully identified a Phase III formulation with a reduced SLS content, which when administered following a low-fat meal, gave comparable pharmacokinetic exposure to the Phase I/II formulation administered under the same conditions.Conclusions: Our novel ‘Make and Test in Parallel’ approach enabled optimization of GDC-0810 formulation in a time- and cost-efficient fashion. [ABSTRACT FROM AUTHOR]
Databáze: Complementary Index
Externí odkaz: